Subscribe to RSS
DOI: 10.1055/s-0039-1690772
Synthesis and Biological Evaluation of Novel 2-Substituted Analogues of (–)-Pentenomycin I
Publication History
Received: 31 October 2019
Accepted after revision: 27 November 2019
Publication Date:
02 January 2020 (online)
Published as part of the Special Section 11th EuCheMS Organic Division Young Investigator Workshop
Abstract
A library of novel 2-substituted derivatives of the antibiotic natural product pentenomycin I is presented. The new collection of analogues is divided in two main classes, 2-alkynyl- and 2-aryl- derivatives, which are accessed by the appropriate type of palladium-catalyzed cross-coupling reaction of the 2-iodo-protected pentenomycin I with suitable nucleophiles. The new derivatives were tested for their activity against certain types of bacteria and one of them, compound 8h, was found to exhibit significant inhibitory activity against several Gram-positive bacteria but also displayed cytotoxic activity against eukaryotic cell lines.
#
(–)-Pentenomycin I (1a) was first isolated from the culture broth of Streptomyces eurythermus MCRL 0738, by Umino and co-workers in 1973 (Figure [1]).[1] The said compound is a principal member of a broader family of cyclopentenoid antibiotics, which possess moderate activity against Gram-positive and Gram-negative bacteria.[1a] [2] Over the past few years, we[3] and others[4] have demonstrated the potential of 2-halogenated pentenomycin as suitable precursor for derivatization, thus leading to new cyclopentenones with potentially improved biological profile.
Herein, we report a systematic effort to synthesize a series of analogues of the natural antibiotic, covering a broad range of stereochemical demand and introducing a variety of functional groups. In the context of our research on the development of new methodologies to access chiral cyclopentenones from sugar-derived synthons, we have described the synthesis of (–)-pentenomycin I through an oxidative elimination process on suitable ammonium salts (Scheme [1], sequence 5 → 6 → 1a).[5] Unexpectedly, we observed that when iodide was used as the counterion in the ammonium salt 5, the respective 2-iodo-protected pentenomycin 7 was afforded. This ‘undesirable’ side product perfectly served the purposes of our synthetic plan to prepare a library of derivatives of the natural antibiotic in order to improve its moderate biological activity. In doing so, palladium-catalyzed cross-coupling reactions were thought to be the most suitable means, a fact supported by the work of Negishi and Johnson on related cross-coupling reactions of 2-iodo-cycloalkenones.[4]
The first class of derivatives we envisaged was the 2-alkynyl-substituted pentenomycins accessible via the well-established Sonogashira reaction.[6] Indeed, under typical reaction conditions,[7] the coupling of 2-iodopentenomycin 7 with various terminal alkynes 9a–i (see general reaction scheme in Table [1]), in the presence of CuI and catalytic amounts of [Pd(PPh3)2Cl2], delivered the desired products in good to excellent yield. After removal of both protecting groups, in one operation, under strongly acidic conditions the final 2-alkynyl-pentenomycins 8a–i were obtained.
a To 7 (0.18 mmol) in THF (3.5 mL) were added successively the corresponding alkyne (0.36 mmol), CuI (10 mg, 0.05 mmol), i Pr2NH (0.13 mL, 0.91 mmol), and [Pd(PPh3)2Cl2] (8 mg, 0.01 mmol). The reaction proceeded at 25 °C for 1–2 h.
b 90% aqueous TFA at 0–25 °C.
In the light of the tabulated results, it is easily deduced that our iodo-cyclopentenone precursor 7 operated as a perfect coupling partner, leading to the anticipated products 10 in excellent yields (72–90%) under the described reaction conditions. A variety of substituted aryl alkynes (Table [1], entries 1–6) was incorporated as the alkyne component bearing a range of functional groups of various stereochemical and electronical profiles. In every case, the desired coupling product was efficiently delivered and isolated by column chromatography. In the same vein, alkyl-substituted terminal alkynes were coupled effectively with protected iodo-pentenomycin 7 in yields ranging from 72–85%, under the same reaction conditions (Table [1], entries 7–9).
Natural product analogues 8a–i were obtained after acidic treatment in 90% aqueous TFA, ensuring removal of both the triphenylmethyl ether and the acetal protecting groups. Due to the enhanced lipophilic character of the produced derivatives, a simple purification by column chromatography was enough to provide a material of appropriate purity (>95%) for biological testing.
Next, we proceeded with the 2-aryl-sustituted pentenomycin derivatives 13a–h that we intended to access via a Suzuki reaction between 7 and the corresponding arylboronic acids 11a–h (see general reaction scheme in Table [2]),[8] followed by global deprotection.
a To 7 (0.18 mmol) in THF (2.25 mL) and H2O (0.75 mL) were added successively the corresponding boronic acid (0.27 mmol), Ag2O (67 mg, 0.29 mmol), Ph3As (12 mg, 0.04 mmol), and [Pd(PPh3)2Cl2] (7 mg, 0.018 mmol). The reaction proceeded at 25 °C for 1–2 h.
b 90% aqueous TFA 0 to 25 °C.
c NR: no reaction.
After screening several catalytic systems, we found that the combination of [Pd(PPh3)2Cl2] and Ph3As as the ligand was the optimum one for a clean conversion into the coupling product.[9] In the presence of the said catalyst and Ag2O, as the base, in a solvent system THF/H2O (3:1), the coupling of 2-iodo-enone 7 with various aryl boronic acids 11a–h was successfully accomplished. The reaction with moderately to electron-rich nucleophiles (Table [2], entries 1, 2, and 4–8) was realized in excellent yields (82–99%). Even rather deactivated boronic acids reacted smoothly under the described reaction conditions (Table [2], entry 3). In contrast, electron-deficient boronic acids such as 2,6-difluorophenyl boronic acid (11i) and 3-pyridylboronic acid (11j) gave no reaction with any of the screened catalytic systems. Global deprotection of the coupling products 12a–h afforded, after typical purification, the unprotected 2-aryl-pentenomycins 13a–h in 59–99% yield.
The antimicrobial activity of the new compounds was tested against three representative strains, one Gram-positive and two Gram-negatives, namely Staphylococcus aureus strain Newman, Escherichia coli K12, and Pseudomonas aeruginosa PA14 (Table [3]). Due to solubility limits, the compounds were tested at the maximum soluble concentration. The designed derivatives 8a–i and 13a–h were found not to exhibit any antimicrobial effect against E. coli and P. aeruginosa, indicating that Gram-negative strains are not sensitive to the action of the aforementioned compounds. In contrast, derivatives 8a, 8d, 8f, and 8h exhibited moderate to good inhibition of the growth of S. aureus, which was superior of the one exerted by the natural product 1a (Table [3]). The observed difference in activity among the two classes of bacteria may be attributed to the difference in their type of cell wall and the ability of the compounds to penetrate them, as well as the reduction of the intracellular concentration of the compounds by efflux pumps.
Based on a recent literature report,[10] the antimicrobial activity of 2-phenyl-pentenomycin (analogue 13a, Table [2]) against several strains, including S. aureus, Enterococcus faecium, and P. aeruginosa, was attenuated compared to the original natural product. By analogy, we observed that when an aromatic group was introduced at the α-position (compounds 13a–h), the antimicrobial activity was completely abolished (Table [3]). However, the activity was restored when an intermediate linker or a long chain was incorporated, such as in 8a, 8d, 8f, and 8h. More specifically, compound 8h, which bears a long aliphatic chain of ten carbon atoms, proved to be the most potent antimicrobial agent. The certain length and the flexibility of this chain is suspected to be the reason for its activity, while 8i, a derivative with a shorter chain by three carbon atoms, is inactive. Finally, derivatives 8d and 8f, which have an aromatic ring connected to the triple bond and bear a halogen at meta or para position, are active but less potent.
In order to test the activity of the designed analogues against additional Gram-positive strains, the most potent inhibitor 8h was screened against the pathogens indicated in Table [4]. The compound does not show any antimicrobial activity against Enterococcus faecium and Enterococci faecalis, as well as against Mycobacterium smegmatis at concentrations below 35 μg/mL. Noteworthy, 8h exhibits a minimum inhibitory concentration (MIC) of 9 μg/mL against Streptococcus pneumoniae, making it one of the most active derivatives of pentenomycin I reported in the literature so far. Interestingly, it shows the same MIC value against a penicillin-resistant strain of S. pneumoniae (PRSP), thus excluding possible cross-resistance.
a PRSP: penicillin-resistant S. pneumoniae.
b VRE: vancomycin-resistant Enterococcus faecium.
Finally, we tested the viability of three human cell lines (A549, HEK293, and HepG2) after treatment with compound 8h. The compound shows cytotoxic effects against the selected cell lines at 25 μΜ (Table [5]), indicating that further structural optimization is required to tackle this drawback. On the other hand, a deeper exploration of the potential of compound 8h to act as an anticancer agent is worthy of being undertaken.
In summary, we successfully synthesized a small library of 2-alkynyl, and 2-aryl-derivatized pentenomycins based on typical palladium-catalyzed coupling reactions.[11] The novel analogues of the natural antibiotic were tested for their antimicrobial activity against both, Gram-positive and Gram-negative bacteria. 2-Aryl-modified pentenomycins show no special activity against both types of bacteria, while from the 2-alkynylated derivatives, the one bearing a long aliphatic chain of ten carbon atoms, 8h, proved to be a strong inhibitor of Gram-positive S. aureus and S. pneumoniae strains. The length of the aliphatic chain was demonstrated to be crucial as the corresponding analogue with a shorter chain by three carbon atoms, 8i, showed no activity. In addition, compound 8h shows cytotoxic effect against certain cell lines, some of them being cancer cells, indicating potential anticancer action.
#
Acknowledgment
Victoria Schmitt, Dennis Thomas Jener, and Jeanine Jung are thanked for the technical support.
Supporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0039-1690772.
- Supporting Information
-
References and Notes
- 1a Umino K, Furumai T, Matsuzawa N, Awataguchi Y, Ito Y, Okuda T. J. Antibiot. 1973; 26: 506
- 1b Umino K, Takeda N, Ito Y, Okuda T. Chem. Pharm. Bull. 1974; 22: 1233
- 2 Umino K, Yamaguchi T, Ito Y. Chem. Pharm. Bull. 1974; 22: 2113
- 3 Christos Stathakis, Dissertation; Aristotle University of Thessaloniki: Greece, 2007.
- 4a Miller MW, Johnson CR. J. Org. Chem. 1997; 62: 1582
- 4b Negishi E. J. Organomet. Chem. 1999; 576: 179
- 4c Negishi E, Tan Z, Liou S.-Y, Liao B. Tetrahedron 2000; 56: 10197
- 4d Pohmakotr M, Kambutong S, Tuchinda P, Kuhakarn C. Tetrahedron 2008; 64: 6315
- 5a Gallos JK, Damianou KC, Dellios CC. Tetrahedron Lett. 2001; 42: 5769
- 5b Gallos JK, Stathakis CI, Kotoulas SS, Koumbis AE. J. Org. Chem. 2005; 70: 6884
- 6a Sonogashira K, Tohda Y, Hagihara N. Tetrahedron Lett. 1975; 16: 4467
- 6b Sonogashira K. J. Organomet. Chem. 2002; 653: 46
- 7 Typical Procedure for the Sonogashira Coupling 2-Iodopentenomycin (7, 100 mg, 0.181 mmol, 1.0 equiv) was dissolved in THF (3.5 mL) and Pd(PPh3)2Cl2 (8 mg, 0.011 mmol, 0.06 equiv) and CuI (10 mg, 0.05 mmol, 0.3 equiv) were added successively. The mixture was deoxygenated and flashed with argon carefully and then was cooled to 0 °C. 1-Decyne (65.3 μL, 0.362 mmol, 2.0 equiv) was added dropwise, followed by addition of i Pr2NH (0.13 mL, 0.905 mmol, 5 equiv). The reaction mixture was stirred at room temperature for 2 h before it was diluted with EtOAc and acidified with 1 N HCl. The organic layer was separated, and the aqueous layer was extracted with EtAOc (2 × 10 mL). The combined organic layers were dried over Na2SO4. The solvent was removed in vacuo, and the residue was purified by flash column chromatography (hexanes/EtOAc, 15:1) to afford the enone 10h (87mg) in 85% yield. Next, compound 10h was dissolved in a mixture 90% TFA/H2O (2.0 mL) at 0 °C, and the resulting solution was stirred for 90 min at this temperature. Upon completion of deprotection, as determined by TLC, volatiles were removed under reduced pressure. The residue was dissolved in methanol and evaporated till dry. The above procedure was repeated twice. The residue was purified by flash column chromatography using EtOAc/MeOH (9:1) as the eluent to afford 8h as a yellow sticky oil (42 mg, 96% yield). 1H NMR (500 MHz, CD3OD): δ = 7.53 (d, J = 3.0 Hz, 1 H), 4.74 (d, J = 3.0 Hz, 1 H), 3.69 (d, J = 10.8 Hz, 1 H), 3.55 (d, J = 10.8 Hz, 1 H), 2.40 (t, J = 7.1 Hz, 2 H), 1.60–1.52 (m, 2 H), 1.43 (dq, J = 13.0, 6.7 Hz, 2 H), 1.34–1.29 (m, 8 H), 0.90 (t, J = 6.7 Hz, 3 H). 13C NMR (125 MHz, CD3OD): δ = 204.0, 161.3, 129.7, 98.7, 75.4, 70.4, 70.0, 63.0, 31.6, 28.9, 28.8, 28.5, 28.1, 22.3, 18.7, 13.0. FTIR (neat): 3462, 2913, 2234, 1738, 1492, 1245, 704 cm–1. [α]D 25 +13.6° (c 1.57 EtOH). HRMS (ESI): m/z [M – H]– calcd for C16H23O4: 279.1596; found: 279.1589.
- 8 Typical Procedure for the Suzuki Reaction 2-Iodopentenomycin (7, 100 mg, 0.181 mmol, 1.0 equiv) was dissolved in a mixture of THF (2.5 mL) and H2O (0.75 mL). Naphthalene-1-boronic acid (47 mg, 0.272 mmol, 1.5 equiv), Ag2O (67 mg, 0.29 mmol, 1.6 equiv), Ph3As (12 mg, 0.04 mmol, 0.2 equiv), and Pd(PPh3)2Cl2 (7 mg, 0.018 mmol, 0.1 equiv) were added successively, and the reaction was stirred at ambient temperature for 3 h. Upon completion the mixture was filtered through Celite. The filtrate was concentrated under reduced pressure and purified by flash column chromatography (hexanes/EtOAc, 15:1) to afford the respective enone 12d (100 mg, 99% yield). Next, compound 12d was dissolved in a mixture of 90% TFA/H2O at 0 °C, and the resulting solution was stirred for 90 min at this temperature. When the reaction was completed as determined by TLC, volatiles were removed under reduced pressure, and the residue was dissolved in methanol and evaporated down. The above procedure was repeated twice, and the residue was purified by flash column chromatography using EtOAc/MeOH (9:1) as the eluent. Derivative 13d was afforded as brown solid (32 mg, 67% yield, mp 52–55 °C). 1H NMR (500 MHz, CD3OD): δ = 7.89 (d, J = 8.0 Hz, 2 H), 7.82 (d, J = 8.3 Hz, 1 H), 7.69 (d, J = 2.8 Hz, 1 H), 7.49 (t, J = 7.6 Hz, 2 H), 7.46–7.43 (m, 1 H), 7.38 (d, J = 7.1 Hz, 1 H), 4.97 (d, J = 2.8 Hz, 1 H), 3.89 (d, J = 10.5 Hz, 1 H), 3.73 (d, J = 10.5 Hz, 1 H). 13C NMR (125 MHz, CD3OD): δ = 205.7, 160.2, 144.7, 133.6, 131.2, 129.3, 128.6, 127.9, 126.5, 125.8, 125.6, 125.1, 124.7, 76.2, 70.3, 63.4. FTIR (neat): 3388, 2924, 2852, 1715, 1509, 1141, 778 cm–1. [α]D 25 –20.5° (c 1.46 EtOH). HRMS (ESI): m/z [M – H]– calcd for C16H13O4: 269.0814; found: 269.0819.
- 9a Ruel FS, Braun MP, Johnson WS. Org. Synth., Coll. Vol. X 2004; 467
- 9b Miyaura N, Suzuki A. Chem. Rev. 1995; 95: 2457
- 10 Kamishima T, Suzuki M, Aoyagi S, Watanabe T, Koseki Y, Kasai H. Tetrahedron Lett. 2019; 60: 1375
- 11 Antibacterial Testing Compounds were prepared as DMSO stock solutions, and minimum inhibitory concentrations (MIC) were determined as described in the literature.12 Bacteria were handled according to standard procedures and were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) or were part of our internal strain collection. In brief, bacterial cultures were diluted in Tryptic Soy Broth (TSB; 1.7% peptone casein, 0.3% peptone soymeal, 0.25% glucose, 0.5% NaCl, 0.25% K2HPO4; pH 7.3; for Enterococci and Streptococci), Luria Broth (LB; 0.05% sodium chloride, 1.0% tryptone, and 0.5% yeast extract for S. aureus, E. coli, and P. aeruginosa), BBL Middlebrook 7H9 with glycerol (0.1% w/v casitone, 5.6 μg/mL palmitic acid, 5 mg/mL bovine serum albumin, 4 μg/mL catalase; for M. smegmatis), or Müller-Hinton broth (0.2% beef infusion solids, 1.75% casein hydrolysate, 0.15% starch; pH 7.4; for all other listed bacteria) to achieve a final inoculum of approximately 104 to 105 colony-forming units (cfu)/mL. Compounds were tested in serial dilution (0.06–128 μM) in 96-well plates, and MIC values were determined by visual inspection after 16–48 h incubation at 37 °C. MTT Assay HepG2 (human hepatocellular carcinoma), HEK293 (human embryonal kidney), and A549 (human lung carcinoma) cells (2 × 105 cells per well) were seeded in 24-well in flat-bottomed plates. Culturing of cells, incubations and OD measurements were performed as described previously with small modification.13 After seeding for 24 h, the incubation was started by the addition of compounds in a final DMSO concentration of 1%. The living cell mass was quantified after 48 h. Rifampicin was used as negative control, doxorubicin as positive control. Full experimental details for the synthesis of all pentenomycin derivatives, as well as pictures of 1H NMR and 13C NMR spectra thereof are provided in the Supporting Information section.
- 12 Hüttel S, Testolin G, Herrmann J, Planke T, Gille F, Moreno M, Stadler M, Brönstrup M, Kirschning A, Müller R. Angew. Chem. Int. Ed. 2017; 56: 12760
- 13 Haupenthal J, Baehr C, Zeuzem S, Piiper A. Int. J. Cancer 2007; 121: 206
-
References and Notes
- 1a Umino K, Furumai T, Matsuzawa N, Awataguchi Y, Ito Y, Okuda T. J. Antibiot. 1973; 26: 506
- 1b Umino K, Takeda N, Ito Y, Okuda T. Chem. Pharm. Bull. 1974; 22: 1233
- 2 Umino K, Yamaguchi T, Ito Y. Chem. Pharm. Bull. 1974; 22: 2113
- 3 Christos Stathakis, Dissertation; Aristotle University of Thessaloniki: Greece, 2007.
- 4a Miller MW, Johnson CR. J. Org. Chem. 1997; 62: 1582
- 4b Negishi E. J. Organomet. Chem. 1999; 576: 179
- 4c Negishi E, Tan Z, Liou S.-Y, Liao B. Tetrahedron 2000; 56: 10197
- 4d Pohmakotr M, Kambutong S, Tuchinda P, Kuhakarn C. Tetrahedron 2008; 64: 6315
- 5a Gallos JK, Damianou KC, Dellios CC. Tetrahedron Lett. 2001; 42: 5769
- 5b Gallos JK, Stathakis CI, Kotoulas SS, Koumbis AE. J. Org. Chem. 2005; 70: 6884
- 6a Sonogashira K, Tohda Y, Hagihara N. Tetrahedron Lett. 1975; 16: 4467
- 6b Sonogashira K. J. Organomet. Chem. 2002; 653: 46
- 7 Typical Procedure for the Sonogashira Coupling 2-Iodopentenomycin (7, 100 mg, 0.181 mmol, 1.0 equiv) was dissolved in THF (3.5 mL) and Pd(PPh3)2Cl2 (8 mg, 0.011 mmol, 0.06 equiv) and CuI (10 mg, 0.05 mmol, 0.3 equiv) were added successively. The mixture was deoxygenated and flashed with argon carefully and then was cooled to 0 °C. 1-Decyne (65.3 μL, 0.362 mmol, 2.0 equiv) was added dropwise, followed by addition of i Pr2NH (0.13 mL, 0.905 mmol, 5 equiv). The reaction mixture was stirred at room temperature for 2 h before it was diluted with EtOAc and acidified with 1 N HCl. The organic layer was separated, and the aqueous layer was extracted with EtAOc (2 × 10 mL). The combined organic layers were dried over Na2SO4. The solvent was removed in vacuo, and the residue was purified by flash column chromatography (hexanes/EtOAc, 15:1) to afford the enone 10h (87mg) in 85% yield. Next, compound 10h was dissolved in a mixture 90% TFA/H2O (2.0 mL) at 0 °C, and the resulting solution was stirred for 90 min at this temperature. Upon completion of deprotection, as determined by TLC, volatiles were removed under reduced pressure. The residue was dissolved in methanol and evaporated till dry. The above procedure was repeated twice. The residue was purified by flash column chromatography using EtOAc/MeOH (9:1) as the eluent to afford 8h as a yellow sticky oil (42 mg, 96% yield). 1H NMR (500 MHz, CD3OD): δ = 7.53 (d, J = 3.0 Hz, 1 H), 4.74 (d, J = 3.0 Hz, 1 H), 3.69 (d, J = 10.8 Hz, 1 H), 3.55 (d, J = 10.8 Hz, 1 H), 2.40 (t, J = 7.1 Hz, 2 H), 1.60–1.52 (m, 2 H), 1.43 (dq, J = 13.0, 6.7 Hz, 2 H), 1.34–1.29 (m, 8 H), 0.90 (t, J = 6.7 Hz, 3 H). 13C NMR (125 MHz, CD3OD): δ = 204.0, 161.3, 129.7, 98.7, 75.4, 70.4, 70.0, 63.0, 31.6, 28.9, 28.8, 28.5, 28.1, 22.3, 18.7, 13.0. FTIR (neat): 3462, 2913, 2234, 1738, 1492, 1245, 704 cm–1. [α]D 25 +13.6° (c 1.57 EtOH). HRMS (ESI): m/z [M – H]– calcd for C16H23O4: 279.1596; found: 279.1589.
- 8 Typical Procedure for the Suzuki Reaction 2-Iodopentenomycin (7, 100 mg, 0.181 mmol, 1.0 equiv) was dissolved in a mixture of THF (2.5 mL) and H2O (0.75 mL). Naphthalene-1-boronic acid (47 mg, 0.272 mmol, 1.5 equiv), Ag2O (67 mg, 0.29 mmol, 1.6 equiv), Ph3As (12 mg, 0.04 mmol, 0.2 equiv), and Pd(PPh3)2Cl2 (7 mg, 0.018 mmol, 0.1 equiv) were added successively, and the reaction was stirred at ambient temperature for 3 h. Upon completion the mixture was filtered through Celite. The filtrate was concentrated under reduced pressure and purified by flash column chromatography (hexanes/EtOAc, 15:1) to afford the respective enone 12d (100 mg, 99% yield). Next, compound 12d was dissolved in a mixture of 90% TFA/H2O at 0 °C, and the resulting solution was stirred for 90 min at this temperature. When the reaction was completed as determined by TLC, volatiles were removed under reduced pressure, and the residue was dissolved in methanol and evaporated down. The above procedure was repeated twice, and the residue was purified by flash column chromatography using EtOAc/MeOH (9:1) as the eluent. Derivative 13d was afforded as brown solid (32 mg, 67% yield, mp 52–55 °C). 1H NMR (500 MHz, CD3OD): δ = 7.89 (d, J = 8.0 Hz, 2 H), 7.82 (d, J = 8.3 Hz, 1 H), 7.69 (d, J = 2.8 Hz, 1 H), 7.49 (t, J = 7.6 Hz, 2 H), 7.46–7.43 (m, 1 H), 7.38 (d, J = 7.1 Hz, 1 H), 4.97 (d, J = 2.8 Hz, 1 H), 3.89 (d, J = 10.5 Hz, 1 H), 3.73 (d, J = 10.5 Hz, 1 H). 13C NMR (125 MHz, CD3OD): δ = 205.7, 160.2, 144.7, 133.6, 131.2, 129.3, 128.6, 127.9, 126.5, 125.8, 125.6, 125.1, 124.7, 76.2, 70.3, 63.4. FTIR (neat): 3388, 2924, 2852, 1715, 1509, 1141, 778 cm–1. [α]D 25 –20.5° (c 1.46 EtOH). HRMS (ESI): m/z [M – H]– calcd for C16H13O4: 269.0814; found: 269.0819.
- 9a Ruel FS, Braun MP, Johnson WS. Org. Synth., Coll. Vol. X 2004; 467
- 9b Miyaura N, Suzuki A. Chem. Rev. 1995; 95: 2457
- 10 Kamishima T, Suzuki M, Aoyagi S, Watanabe T, Koseki Y, Kasai H. Tetrahedron Lett. 2019; 60: 1375
- 11 Antibacterial Testing Compounds were prepared as DMSO stock solutions, and minimum inhibitory concentrations (MIC) were determined as described in the literature.12 Bacteria were handled according to standard procedures and were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) or were part of our internal strain collection. In brief, bacterial cultures were diluted in Tryptic Soy Broth (TSB; 1.7% peptone casein, 0.3% peptone soymeal, 0.25% glucose, 0.5% NaCl, 0.25% K2HPO4; pH 7.3; for Enterococci and Streptococci), Luria Broth (LB; 0.05% sodium chloride, 1.0% tryptone, and 0.5% yeast extract for S. aureus, E. coli, and P. aeruginosa), BBL Middlebrook 7H9 with glycerol (0.1% w/v casitone, 5.6 μg/mL palmitic acid, 5 mg/mL bovine serum albumin, 4 μg/mL catalase; for M. smegmatis), or Müller-Hinton broth (0.2% beef infusion solids, 1.75% casein hydrolysate, 0.15% starch; pH 7.4; for all other listed bacteria) to achieve a final inoculum of approximately 104 to 105 colony-forming units (cfu)/mL. Compounds were tested in serial dilution (0.06–128 μM) in 96-well plates, and MIC values were determined by visual inspection after 16–48 h incubation at 37 °C. MTT Assay HepG2 (human hepatocellular carcinoma), HEK293 (human embryonal kidney), and A549 (human lung carcinoma) cells (2 × 105 cells per well) were seeded in 24-well in flat-bottomed plates. Culturing of cells, incubations and OD measurements were performed as described previously with small modification.13 After seeding for 24 h, the incubation was started by the addition of compounds in a final DMSO concentration of 1%. The living cell mass was quantified after 48 h. Rifampicin was used as negative control, doxorubicin as positive control. Full experimental details for the synthesis of all pentenomycin derivatives, as well as pictures of 1H NMR and 13C NMR spectra thereof are provided in the Supporting Information section.
- 12 Hüttel S, Testolin G, Herrmann J, Planke T, Gille F, Moreno M, Stadler M, Brönstrup M, Kirschning A, Müller R. Angew. Chem. Int. Ed. 2017; 56: 12760
- 13 Haupenthal J, Baehr C, Zeuzem S, Piiper A. Int. J. Cancer 2007; 121: 206